Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate initial clinical safety, device functionality and effectiveness of the Edwards Transcatheter Atrial Shunt System.
The early feasibility study of the Edwards Transcatheter Atrial Shunt System is a multi-center, prospective, early feasibility study to evaluate initial clinical safety, device functionality, and effectiveness of the Edwards Transcatheter Atrial Shunt System.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Edwards Transcatheter Atrial Shunt System | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Transcatheter Atrial Shunt System | Device | Transcatheter treatment of symptomatic left heart failure patients |
|
| Measure | Description | Time Frame |
|---|---|---|
| Rate of major cardiac/cerebrovascular/renal events and re-intervention (Safety Endpoint) | Composite of major adverse cardiac, cerebrovascular, renal events (MACCRE) and re-intervention for study device related complications at 30 days. | 30 days |
| Measure | Description | Time Frame |
|---|---|---|
| Rate at which device is successfully implanted (Device Success) | Device is deployed as intended and the delivery system is successfully removed as intended at the time of the patient's exit from the implant procedure room. | Day 0 |
| Rate at which device is patent and subject is discharged from hospital without the need for additional intervention for the device (Procedural Success) |
Not provided
Inclusion Criteria:
Symptomatic Heart Failure (HF):
On stable Guideline Directed Medical Therapy (GDMT) for heart failure
At rest: elevated LAP (or PCWP) of > 15 mmHg and LAP (or PCWP) exceeds right atrial pressure (RAP) by > 5 mmHg AND/OR supine ergometer exercise, elevated LA (or PCWP) pressure of > 25 mmHg and LA (or PCWP) exceeds right atrial pressure (RAP) by > 10 mmHg
Left Ventricular Ejection Fraction (LVEF) ≤ 40%
Pulmonary Vascular Resistance (PVR) < 4.0 WU
Exclusion Criteria:
Severe HF:
Valve disease: MR > 3+ or > moderate MS, TR > 2+, AR > 2+ or > moderate AS
MI or therapeutic invasive cardiac procedure < 3 months
TIA, stroke, CRT implanted < 6 months
RV dysfunction > mild by TTE OR TAPSE < 1.2 OR RV size ≥ LV size by TTE, OR right ventricular fractional area change (RVFAC) ≤ 25%
Dialysis OR renal dysfunction (S-CR > 2.5 mg/dl OR eGFR < 25 ml/min/1.73m2)
6MWT < 50m OR > 600m
Active endocarditis or infection < 3 months
Mean Right Atrial Pressure (mRAP) > 15 mmHg at rest
Body Mass Index (BMI) ≥ 45 kg/m2
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UC San Diego Health | La Jolla | California | 92037 | United States | ||
| University California San Francisco |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40019407 | Derived | Fioretti F, Hibbert B, Eckman PM, Simard T, Labinaz M, Nazer B, Wiley M, Gupta B, Sauer AJ, Shah H, Sorajja P, Pineda AM, Missov E, Aldaia L, Koulogiannis K, Gray WA, Zahr F, Butler J. Left Atrial-to-Coronary Sinus Shunting in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The ALT-FLOW Trial (Early Feasibility Study) 2-Year Results. JACC Heart Fail. 2025 Jun;13(6):987-999. doi: 10.1016/j.jchf.2025.02.003. Epub 2025 Feb 11. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Device success with evidence of shunt patency and hospital discharge without the need for additional surgical or percutaneous intervention related to the study device including unacceptable Qp/Qs values. |
| 10 days post-op |
| Rate at which the procedure is successful without major cardiac/cerebrovascular/renal events and re-intervention (Clinical Success) | Procedural success without major adverse cardiac, cerebrovascular, and renal events (MACCRE) and re-intervention for study device related complications at 30 days. | 30 days |
| Change in the ratio of systemic blood flow (Qs) to the pulmonary blood flow (Qp), called "Qp/Qs", from Baseline to Follow Up | Change in Qp/Qs value from Baseline to Follow Up (3Month, 6Month) | 3 months, 6 months |
| Change in pulmonary capillary wedge pressure (PCWP) from Baseline to Follow Up | Change in PCWP value from Baseline to Follow Up (3Month, 6Month) | 3 months, 6 months |
| Change in mean systolic & diastolic pulmonary artery pressure (PAP) and change in mean right atrial pressure (RAP) from Baseline to Follow Up | Change in PAP and RAP values from Baseline to Follow Up (3Month, 6Month) under the same test conditions (e.g. comparison in the value at rest at baseline, to at rest at follow up; comparison in the value at exercise at baseline, to at exercise at follow up) | 3 months, 6 months |
| Change in Pulmonary Vascular Resistance (PVR) from Baseline to Follow Up | Change in PVR value from Baseline to Follow Up (3Month, 6Month) under the same test conditions (e.g. comparison in the value at rest at baseline, to at rest at follow up; comparison in the value at exercise at baseline, to at exercise at follow up) | 3 months, 6 months |
| Change in two parameters related to Tricuspid Annular Plane Excursion (TAPSE) from Baseline to Follow Up | Change in two parameters from Baseline to Follow Up (3Month, 6Month): 1. "TAPSE", Tricuspid Annular Plane Excursion 2. "TAPSE/sPAP", Tricuspid Annular Plane Excursion (TAPSE) divided by the systolic pulmonary Artery Pressure (sPAP) | 3 months, 6 months |
| San Francisco |
| California |
| 94143 |
| United States |
| University of Florida Health - Jacksonville | Jacksonville | Florida | 32209 | United States |
| St. Vincent Medical Group | Indianapolis | Indiana | 46260 | United States |
| Kansas University Medical Center | Kansas City | Kansas | 66160 | United States |
| Abbott Northwestern | Minneapolis | Minnesota | 55407 | United States |
| Mayo Clinic | Rochester | Minnesota | 55905 | United States |
| Montefiore Medical Center | The Bronx | New York | 10467 | United States |
| Atrium Health | Charlotte | North Carolina | 28203 | United States |
| The Christ Hospital | Cincinnati | Ohio | 45219 | United States |
| The Ohio State University Medical Center | Columbus | Ohio | 43210 | United States |
| Oregon Health and Science University | Portland | Oregon | 97239 | United States |
| Lankenau Institute for Medical Research | Wynnewood | Pennsylvania | 19096 | United States |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | United States |
| Swedish Medical Center | Seattle | Washington | 98122 | United States |
| ID | Term |
|---|---|
| D006333 | Heart Failure |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided